Harbour BioMed inks $350 million deal for rights to A167
USA-based Harbour BioMed has entered into an exclusive strategic partnership with China’s Sichuan Kelun-Biotech Biopharmaceutical to develop and commercialize A167
Member News
October 9, 2024
A Fresh New Look at Labshares: Office Upgrade at 90 Bridge Street
Labshares News
May 27, 2025
Labshares Expands Leadership Team with New Hire and Internal Promotion
